AGM/EGMJun 4, 2026, 04:37 PM
Akari Therapeutics Announces 2026 Annual General Meeting
AI Summary
Akari Therapeutics Plc has filed its Definitive Proxy Statement for the 2026 Annual General Meeting (AGM) scheduled for June 30, 2026. The meeting will cover standard corporate business including the review of the 2025 annual report, director re-elections, and auditor appointments. Notably, shareholders will vote on resolutions related to share and warrant issuances under specific agreements and the authorization for directors to allot shares. The company urges shareholders to submit their proxies by June 26, 2026, with a separate deadline for ADS holders.
Key Highlights
- Akari Therapeutics Plc announces its 2026 Annual General Meeting (AGM) to be held on June 30, 2026, in London.
- The AGM will include resolutions for receiving the 2025 annual report, approving remuneration reports and policies, re-electing directors, and ratifying auditors.
- Key resolutions include approving the issuance of shares and warrants under various agreements, and authorizing directors to allot shares.
- Shareholders are urged to vote by proxy by June 26, 2026; ADS holders have a separate proxy deadline of June 18, 2026.
- The Board of Directors unanimously recommends voting FOR all proposed resolutions.
Price Impact
More from AKTX